



JCS7 Rec'd PCT/PTO 28 FEB 2002

PCT

PATENT

Attorney Docket No.: 27656/37821

10/018437

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Zangemeister-Wittke et al.) I hereby certify that this paper is being
) deposited with the United States Postal
) Service as first class mail, postage
Serial No.: 10/018,437) prepaid, in an envelope addressed to:
) Commissioner for Patents,
) Washington, DC 20231 on this date:
Filed: October 30, 2001)
)
) February 20, 2002
For: Oligonucleotide Derivatives)
Directed Against Human bcl-xL)
and Human bcl-z mRNA)
)
Group Art Unit: TBD) Jeffrey S. Sharp
) Registration No. 31,879
Examiner: TBD) Attorney for Applicants
)
)
)
)

**INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. §§ 1.56, 1.97, AND 1.98**

Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with 37 C.F.R. §1.97 and the continuing duty of disclosure under 37 C.F.R. §1.56, the applicants call to the attention of the examiner the enclosed publications, as listed on the attached Form PTO-1449, which may be considered material to the examination of the above-identified patent application.

Documents A1, B1-B5 and C1-C7 were cited in the international search report of counterpart international patent appl. no. PCT/EP00/03708 (document C8 on the enclosed Form PTO-1449).

This information disclosure statement is not intended to be an admission that a search has been made, that other relevant art does not exist, or that any of the information


disclosed herein constitutes prior art under 35 U.S.C. §102 or 35 U.S.C. §103.

This information disclosure statement is submitted before receipt of a first official action on the merits and consequently should be considered by the Patent Office without payment of a fee [see 37 C.F.R. §1.97(b)]. However, should the Patent Office determine that a fee is due for consideration of this information disclosure statement and accompanying publications, the Patent Office is hereby authorized to charge said fee to Deposit Account No. 13-2855. A duplicate of this paper is enclosed.

Respectfully submitted,


MARSHALL, GERSTEIN & BORUN
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606-6402
(312) 474-6300

By:



Jeffrey S. Sharp
Reg. No.:31,879

February 20, 2002



Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
27656/37821Serial No.
10/018,437**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

Applicant
Zangemeister-Wittke et al.Filing Date
October 30, 2001Group
To be assigned**U.S. PATENT DOCUMENTS**

*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	A1	5,470,974	11/28/95	Summerton et al.	544	118	

FOREIGN PATENT DOCUMENTS

*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation	
							Yes	No
	B1	WO 95/08350	03/30/95	PCT	A61K	48/00		
	B2	WO 95/31470	11/23/95	PCT	C07H	21/02		
	B3	WO 98/18812	05/07/98	PCT	C07H	21/04		
	B4	WO 00/01393	01/13/00	PCT	A61K	31/70		
	B5	WO 00/20432	04/13/00	PCT	C07H	21/04		


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

	C1	Gautschi et al., "Potent Anti-tumor Activity of a BCL-2/BCL-XL Bispecific Antisense Oligonucleotide Against Solid Tumors of Diverse Histological Origin," <i>Proceedings of the American Association for Cancer Research Annual</i> , 41:642 (2000) abstract # 4077.
--	----	--

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 27656/37821	Serial No. 10/018,437
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)			Applicant Zangemeister-Wittke et al.	
			Filing Date October 30, 2001	Group To be assigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
C2	Luedtke <i>et al.</i> , "Antisense Oligonucleotides Targeting Sequences Shared by the Bcl-2 and Bcl-xL Efficiently Downregulate Expression of Both Proteins and Induce Apoptosis of Lung Cancer Cells," <i>Proceedings of the Annual Meeting of the American Association for Cancer Research, US, Philadelphia</i> , 38:170 (1997) abstract #1140.	
C3	Luedtke <i>et al.</i> , "Antisense Oligonucleotides Targeting Sequences Shared by the Bcl-2 and Bcl-xL Efficiently Downregulate Expression of Both Proteins and Induce Apoptosis of Lung Cancer Cells," <i>Proceedings of the Annual Meeting of the American Association for Cancer Research, US, Philadelphia</i> , 39:417 (1998) abstract #2838.	
C4	Obika <i>et al.</i> , "Properties of Novel Oligonucleotide Analogues Containing an Acyclic Nucleoside and a Carbamate Linkage," <i>Bioorganic & Medical Chemistry Letters</i> , 6:1357-1360 (1996).	
C5	Zangemeister-Wittke <i>et al.</i> , "Bcl2 Antisense Oligonucleotide 2009 Synergizes with Chemotherapy on Lung Cancer Cell Lines and has Antitumor Activity against Lung Cancer Xenografts," <i>Proceedings of the American Association for Cancer Research Annual</i> , 39:417 (1998) abstract #2839.	
C6	Zangemeister-Wittke <i>et al.</i> , "Synergistic Cytotoxicity of bcl-2 Antisense Oligodeoxynucleotides and Etoposide, Doxorubicin and Cisplatin on Small-cell Lung Cancer Cell Lines," <i>British Journal of Cancer</i> , 78:1035-1042 (1998).	
C7	Zangemeister-Wittke <i>et al.</i> , "Novel Approaches to the Treatment of Small-cell Lung Cancer," <i>Cell. Mol. Life Sci.</i> , 55:1585-1598 (1999).	
C8	International Search Report, International Application No.: PCT/EP00/03708, International Searching Authority/ European Patent Office.	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	